CALFAN Syndrome Clinical Trial
Official title:
The Effectiveness of Rehabilitation Program in an Ultra-rare Calfan Syndrome
| Verified date | December 2020 |
| Source | Hasan Kalyoncu University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Calfan syndrome is a progressive neurodegenerative systemic disease. It is a rare and difficult disease to diagnose due to the complex symptoms that occur over the years to postpartum. The aim of this study is to investigate the effectiveness of the physiotherapy and rehabilitation program in a rare case with Calfan syndrome.
| Status | Completed |
| Enrollment | 1 |
| Est. completion date | November 17, 2020 |
| Est. primary completion date | October 20, 2020 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - Calfan syndrome Exclusion Criteria: - Any surgery in past six months |
| Country | Name | City | State |
|---|---|---|---|
| Turkey | Hasan Kalyoncu Üniversity | Gaziantep |
| Lead Sponsor | Collaborator |
|---|---|
| Hasan Kalyoncu University |
Turkey,
Lenz D, McClean P, Kansu A, Bonnen PE, Ranucci G, Thiel C, Straub BK, Harting I, Alhaddad B, Dimitrov B, Kotzaeridou U, Wenning D, Iorio R, Himes RW, Kuloglu Z, Blakely EL, Taylor RW, Meitinger T, Kölker S, Prokisch H, Hoffmann GF, Haack TB, Staufner C. SCYL1 variants cause a syndrome with low ?-glutamyl-transferase cholestasis, acute liver failure, and neurodegeneration (CALFAN). Genet Med. 2018 Oct;20(10):1255-1265. doi: 10.1038/gim.2017.260. Epub 2018 Feb 8. — View Citation
Lenz D, Staufner C, Wächter S, Hagedorn M, Ebersold J, Göhring G, Kölker S, Hoffmann GF, Jung-Klawitter S. Generation of an induced pluripotent stem cell (iPSC) line, DHMCi005-A, from a patient with CALFAN syndrome due to mutations in SCYL1. Stem Cell Res. 2019 May;37:101428. doi: 10.1016/j.scr.2019.101428. Epub 2019 Mar 22. — View Citation
Spagnoli C, Frattini D, Salerno GG, Fusco C. On CALFAN syndrome: report of a patient with a novel variant in SCYL1 gene and recurrent respiratory failure. Genet Med. 2019 Jul;21(7):1663-1664. doi: 10.1038/s41436-018-0389-6. Epub 2018 Dec 10. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Trunk Control | The Trunk Disorder Scale (TIS) was used to assess static and dynamic sitting balance and trunk coordination | 3 month | |
| Primary | The severity of ataxia | The International Ataxia Rating Scale (ICARS) was used to determine the severity | 3 month | |
| Primary | The quality of life | The Children's Quality of Life Scale (PedsQL) was used determine to quality of life level. | 3 month | |
| Primary | The Functional Independence | The Functional Independence Scale for Children (WeeFIM) was used determine to independence level. | 3 month | |
| Secondary | Upper extremity functional performance | The 9-Hole Peg test was used to evaluate upper extremity performance | 3 month | |
| Secondary | Upper extremity disability level | the Quick Questionnaire for Arm, Shoulder and Hand Problems (Q-DASH) scale was used to evaluate physical disability and symptoms of upper extremity | 3 month |